Agence France-Presse

European Commission Approves Erbitux® (cetuximab) in Combination with Encorafenib and FOLFOX for First-Line Treatment of Metastatic Colorectal Cancer with BRAF V600E Mutation

Merck, a leading global science and technology company, today announced that the European Commission (EC) approved an update to the Erbitux (cetuximab) EU label on June 26, 2026. Erbitux is now ...
PharmaTimes

EC approves Erbitux combination for first‑line treatment of BRAF V600E‑mutant mCRC

Merck has announced that the European Commission has approved an update to the Erbitux (cetuximab) EU label, extending its ...
Benzinga.com

Johnson & Johnson Therapy Delivers Strong Results In Colorectal Cancer Trial

On Saturday, Johnson & Johnson (NYSE: JNJ) shared new longer follow-up results from the Phase 1b/2 OrigAMI-1 study. The trial is evaluating Rybrevant (amivantamab-vmjw) in combination with FOLFOX or ...
ascopubs.org

Phase III CR-SEQUENCE trial of FOLFOX+panitumumab followed by FOLFIRI+bevacizumab (SEQ1) versus FOLFOX + bevacizumab followed by FOLFIRI + panitumumab (SEQ2) in previously ...

Circulating tumor DNA (ctDNA) clearance as an early indicator of sotorasib + panitumumab efficacy and prognosis in KRAS G12C–mutated colorectal cancer (mCRC): Results from phase 3 CodeBreaK 300.